

Revenues

# Fiscal Note H.B. 106 2020 General Session Rare Disease Advisory Council by Perry, L.



FY 2021

# General, Education, and Uniform School Funds

JR4-5-101

FY 2022

	Ongoing	One-time	Total
Net GF/EF/USF (revexp.)	\$(38,200)	\$0	\$(38,200)

State Government UCA 36-12-13(2)(b)

FY 2020

	2020						
Total Revenues	\$0	\$0	\$0				
Enactment of this legislation likely will not materially impact state revenue.							
Expenditures	FY 2020	FY 2021	FY 2022				
General Fund	\$0	\$38,200	\$38,200				
Total Expenditures	\$0	\$38,200	\$38,200				

Enactment of this legislation could cost the Department of Health \$38,200 from the General Fund ongoing, beginning in Fiscal Year 2021, for council member travel and per diem as well as staff and administrative costs for the new Rare Disease Advisory Council.

	FY 2020	FY 2021	FY 2022
Net All Funds	\$0	\$(38,200)	\$(38,200)

Local Government UCA 36-12-13(2)(c)

Enactment of this legislation likely will not result in direct, measurable costs for local governments.

### Individuals & Businesses

UCA 36-12-13(2)(d)

Enactment of this legislation likely will not result in direct expenditures from tax or fee changes for Utah residents and businesses.

# Regulatory Impact

UCA 36-12-13(2)(e)

Enactment of this legislation likely will not change the regulatory burden for Utah residents or businesses.

Performance Note JR4-2-404

No performance note required for this bill

# **Notes on Notes**

Fiscal notes estimate the direct costs or revenues of enacting a bill. The Legislature uses them to balance the budget. They do not measure a bill's benefits or non-fiscal impacts like opportunity costs, wait times, or inconvenience. A fiscal note is not an appropriation. The Legislature decides appropriations separately.